Galmed PharmaceuticalsEOCN
13F holders, Q4 2025 (December 31)17holders +3
5new positions
2sold out
1famous investor
$0.75avg. 13F price*
At the end of Q4 2025, 17 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings, up 3 from Q3 2025. 5 opened new positions and 2 sold out. The largest holders were Two Sigma Investments, LP ($84K), Citadel Advisors ($29K) and Two Sigma Advisers, LP ($24K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $52K |
| Exits | 2 | $32 |
All 13F filers, Q3 2025 → Q4 2025: 161,174 shares bought and 12,338 shares sold, net +148,836 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Two Sigma Investments, LP | 0.00% | Add +429.0% | 112,147 | $84K |
| Citadel Advisors | 0.00% | Reduce -24.4% | 38,177 | $29K |
| Two Sigma Advisers, LP | 0.00% | New | 31,491 | $24K |
| Two Sigma Securities, LLC | 0.00% | New | 13,602 | $10K |
| Jane Street Group, LLC | 0.00% | New | 12,135 | $9K |
| XTX Topco Ltd | 0.00% | New | 11,048 | $8K |
| UBS Group AG | 0.00% | Add +88.4% | 1,814 | $1K |
| BNP Paribas Financial Markets | 0.00% | New | 900 | $675 |
| Morgan Stanley | 0.00% | Add +204.1% | 298 | $224 |
| SBI Securities Co., Ltd. | 0.00% | No change | 16 | $12 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 14 | $11 |
| Wells Fargo & Company | 0.00% | No change | 9 | $7 |
| Osaic Holdings, Inc. | 0.00% | No change | 5 | $3 |
| Allworth Financial LP | 0.00% | No change | 2 | $2 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 1 | $1 |
| Dogwood Wealth Management LLC | 0.00% | No change | 1 | $1 |
| Tsfg, LLC | 0.00% | No change | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.